| Disease | AND THAT THESE EFFECTS ARE MORE PRONOUNCED THAN THOSE FOLLOWING G. BILOBA.
SIGNIFICANT REDUCTIONS IN FRONTAL 'EYES CLOSED' THETA AND BETA ACTIVITY, WITH ADDITIONAL REDUCTION FOR GINSENG IN THE ALPHA WAVEBAND. THESE FINDINGS DEMONSTRATE FOR THE FIRST TIME THAT P.GINSENG CAN DIRECTLY MODULATE CEREBROELECTRICAL ACTIVITY,
TREATMENTS WAS DICATED BY A LATIN SQUARE WITH 7 DAYS BETWEEN TESTING SESSIONS. THE RESULTS SHOWED THAT GINSENG LED TO A SIGNIFICANT SHORTENING OF THE LATENCY OF THE P300 COMPONENT OF THE EVOKED POTENTIAL. BOTH GINSENG AND GINKGO ALSO LED TO
RESTING POWER WITHIN THE DELTA, THETA, ALPHA, AND BETA WAVEBANDS, WERE ASSESSED IN 15 HEALTHY VOLUNTEERS. EACH PARTICIPANT WAS ASSESSED ON THREE SEPARATE OCCASIONS 4 H AFTER CONSUMING THAT DAY'S TREATMENT. THE ORDER OF PRESENTATION OF THE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, BALANCED CROSSOVER STUDY THE EFFECTS OF SINGLE DOSES OF G. BILOBA (360 MG GK501), P.GINSENG 9200 MG G115), AND AN IDENTICAL PLACEBO, ON AUDITORY-EVOKED POTENTIALS, CONTINGENT NEGATIVE VARIATION (CNV), AND |